The proportions of adverse events in LAM patients were quantified, and the common toxicity events during the mTOR inhibitors therapy were oral mucositis, hyperlipidemia, headache, bone marrow suppression, diarrhea and cough. Here, MTOR is linked to hyperlipidemia.